Fresh analysis indicates that people who stop using new weight-loss injections like Mounjaro or Wegovy may regain lost weight far faster than those who stop conventional diet and exercise plans.
Findings released in a prominent health publication demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People purchasing such drugs must be cognizant of the potential of quick rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a return to original mass in about 18 months.
Weighing Therapies
The analysis, which examined 37 of trials involving over 9,000 of patients, compared the effects of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through diet and exercise generally experience a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Rebound
Doctors suggest the mode of action of the jabs is key to understanding the accelerated regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Health authorities suggest the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the significant potential of weight regain, the therapy is often ongoing.
This opinion is echoed by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," akin to managing conditions like hypertension.
User Testimonies
Users who have come off the jabs explain a sudden resurgence of cravings.
"It felt as if a switch activating and you become starving," said one woman.
The struggle is compounded if users have not developed sustainable dietary or behavioural changes during therapy.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits hinges on ongoing behavioural management.